Neurocrine Biosciences, Inc.

Valuation Analysis

About the Company

Neurocrine Biosciences, Inc. en bref

Neurocrine Biosciences, Inc. (NBIX) is currently trading at 137,99 € with a market capitalization of 13,9 Md €. The trailing P/E ratio stands at 24.31x, with a forward P/E of 12.41x. The 52-week range spans from 106,48 € to 147,83 €; the current price is 6.7% below the yearly high. Year-over-year revenue growth stands at +42.2%. The net profit margin stands at 21.55%.

💰 Dividende

Neurocrine Biosciences, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

29 analystes évaluent Neurocrine Biosciences, Inc. (NBIX) au consensus : Achat Fort. L'objectif de cours moyen est de 168,42 €, soit un potentiel de +22.05% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 125,53 € à 218,51 €.

Neurocrine Biosciences, Inc. : la thèse d'investissement en détail

Neurocrine Biosciences, Inc. (NBIX) operates in the Healthcare — specifically Drug Manufacturers - Specialty & Generic — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 42.2% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 64.37%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Free cash flow is positive and net margins stand at 21.55%, meaning reported earnings translate into real cash that can fund buybacks, dividends or strategic acquisitions.

Valorisation en contexte

With a PEG ratio of 0.44, the price-to-earnings multiple is actually below the company's growth rate — classic value-meets-growth territory that Peter Lynch would have called a 'GARP' opportunity.

À surveiller

• The forward P/E of 12.41x is meaningfully below the trailing 24.31x — analysts expect earnings to step up; the next earnings release is the test.
• The analyst consensus price target implies 22.05% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price trades above both the 50- and 200-day moving averages, with 50d above 200d — a classic bullish setup (golden-cross alignment).

Profil de risque

The data points to relatively defensive market behavior, elevated short interest (7.16%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Neurocrine Biosciences, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.